• 文献标题:   A highly sensitive nanobiosensor based on aptamer-conjugated graphene-decorated rhodium nanoparticles for detection of HER2-positive circulating tumor cells
  • 文献类型:   Article
  • 作  者:   SADEGHI M, KASHANIAN S, NAGHIB SM, ASKARI E, HAGHIRALSADAT F, TOFIGHI D
  • 作者关键词:   her2 + circulating tumor cell, graphitebased electrochemical apatasensor, her2 tumor marker diagnosi, breast cancer, rhodium nanoparticle, graphenerhodium nanocomposite
  • 出版物名称:   NANOTECHNOLOGY REVIEWS
  • ISSN:   2191-9089 EI 2191-9097
  • 通讯作者地址:  
  • 被引频次:   13
  • DOI:   10.1515/ntrev-2022-0047
  • 出版年:   2022

▎ 摘  要

Assessment of human epidermal growth factor receptor-2 (HER2) tumor marker status is an impressive factor in screening, diagnosing and monitoring breast cancer (BC). The electrochemical biosensor is a revolutionary method in cancer diagnosis, which is used in this research to detect HER2(+) circulating tumor cells. The electrochemical activity, size, shape, and morphology of the synthesized nanomaterials were analyzed. The hybrid nanocomposite established by the coupling of reduced graphene oxide nanosheets (rGONs) and rhodium nanoparticles (Rh-NPs) on the surface of graphite electrode resulted in improved surface area, electrochemical activity, and biocompatibility. The graphite electrode-based aptasensor (g-aptasensor) demonstrated exceptional performance against HER2-overexpressed SKBR3 cancer cells, with a linear dynamic range of 5.0 to 10.0 x 10(4) cells/mL, an analytical limit of detection (LOD) as low as 1.0 cell/mL, and a limit of quantification (LOQ) of 3.0 cells/mL. The G-rich DNA aptamers can fold into an intermolecular G-quadruplex, which specifically bind to the target molecule. Consequently, the advantages of this highly efficient nanocomposite platform include broad dynamic range, high specificity, selectivity, stability, reproducibility, and low cost. These characteristics indicate that the fabricated nanobiosensor has a high potential for use in detecting and monitoring HER2 level for the care of BC patients and clinical diagnosis.